Solid Tumors (22 companies)

Companies with an active program in Solid Tumors.

Ticker	Company	Therapeutic areas	Programs	Lead stage	Mkt cap	Programs
ADAG	Adagene	Oncology	4	Phase 2	$134M	10
ANTX	AN2 Therapeutics	HematologyInfectious Disease+1 Rare	1	Phase 2	$151M	6
APVO	Aptevo Therapeutics	Oncology	2	Phase 1	$2.2M	8
ARVN	Arvinas	NeurologyOncology Rare	2	Approved	$420M	10
COGT	Cogent Biosciences	HematologyOncology Rare	2	NDA Submitted	$5.51B	7
CHRS	Coherus Oncology	Oncology	1	Approved	$119M	4
CGEN	Compugen	Oncology	1	Phase 3	$186M	7
ERAS	Erasca	Oncology	2	Phase 1	$5.04B	5
EXEL	Exelixis	CardiovascularOncology	3	Approved	$17.0B	23
FATE	Fate Therapeutics	ImmunologyOncology+1 Rare	2	Phase 2	$224M	10
IMRX	Immuneering	Oncology	1	Phase 3	$238M	5
IMNM	Immunome	Oncology Rare	4	NDA Submitted	$2.13B	9
MDNAF	Medicenna Therapeutics	Oncology	1	Phase 2	$29.5M	10
INKT	MiNK Therapeutics	ImmunologyOncology+1 Rare	1	Phase 2	$52.8M	8
NBP	NovaBridge Biosciences	OncologyOphthalmology	1	Phase 2	$106M	7
NVCT	Nuvectis Pharma	HematologyOncology+1 Rare	1	Phase 3	$719M	9
KTTA	Pasithea Therapeutics	NeurologyOncology Rare	1	Phase 1	$19.3M	4
CATX	Perspective Therapeutics	Oncology	1	Phase 1	$95.9M	4
PMVP	PMV Pharmaceuticals	Oncology	1	Phase 2	$67.4M	7
RXRX	Recursion Pharmaceuticals	Oncology	3	Phase 2	$2.19B	6
STRO	Sutro Biopharma	Oncology	3	Phase 1	$160M	4
XNCR	Xencor	ImmunologyNeurology+1 Rare	1	Approved	$2.68B	28